Nadph oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof

A compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof:

• Wherein
• A is C6-C20 aryl optionally fused with C1-C20 heterocyclyl, or C1-C20 heteroaryl optionally fused with C1-C20 heterocyclyl, and A is optionally substituted with one or more C1-C10 alkyl, C6-C20 aryl, halogen, OR11, C(O)R11, C(O)OR11, NR11R12, SO2R11, or SO2(OR11);
• B is C1-C10 alkyl, C6-C20 aryl, C1-C20 heteroaryl or C1-C20 heterocyclyl, and B is optionally substituted with one or more C1-C10 alkyl, C6-C20 aryl, C1-C20 heterocyclyl, halogen, OR21, C(O)R21, C(O)OR21, NR21R22, SO2R21, or SO2(OR21), wherein said C1-C10 alkyl is optionally substituted with one or more halogen;
• R11, R12, R21 and R22 independently are H, O, C1-C10 alkyl, or C6-C20 aryl, wherein said C1-C10 alkyl is optionally substituted with one or more halogen;
• is a single bond or double bond;
• n is 0 or 1;
• X is N or C;
• Y is H, OH or NH2;
• Z is nil or C(O);
• R3 and R4 independently are nil, H, C1-C10 alkyl or C6-C20 aryl;
• and
• R5 is nil, H or C1-C10 alkyl.